Guidelines of the Polish Society of Laboratory Diagnosticsand the Polish Lipid Association on laboratory diagnosticsof lipid metabolism disorders. 2024-Reference-Cited by-同舟云学术

Guidelines of the Polish Society of Laboratory Diagnosticsand the Polish Lipid Association on laboratory diagnosticsof lipid metabolism disorders. 2024

Published:2024-03-25 Issue:1 Volume:60 Page:1-24
ISSN:0867-4043
Container-title:Diagnostyka Laboratoryjna
language:
Short-container-title:Diagn Lab.

Author:

Solnica Bogdan¹,Sygitowicz Grażyna²,Sitkiewicz Dariusz²,Jóźwiak Jacek³,Kasperczyk Sławomir⁴,Broncel Marlena⁵,Wolska Anna⁶,Odrowąż-Sypniewska Grażyna⁷,Banach Maciej⁸

Affiliation:

1. Katedra Biochemii Klinicznej, Uniwersytet Jagielloński Collegium Medicum, Kraków, Polska

2. Zakład Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, Polska

3. Zakład Medycyny Rodzinnej i Zdrowia Publicznego, Wydział Lekarski, Uniwersytet Opolski, Opole, Polska

4. Poradnia Chorób Metabolicznych, Centrum Medyczne „Eko-Prof.-Med.”, Miasteczko Śląskie, Polska

5. Klinika Chorób Wewnętrznych i Farmakologii Klinicznej, Uniwersytet Medyczny w Łodzi, Polska

6. Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States

7. Katedra i Zakład Diagnostyki Laboratoryjnej, Collegium Medicum w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu, Polska

8. Zakład Kardiologii Prewencyjnej i Lipidologii, Uniwersytet Medyczny w Łodzi, Polska

Abstract

Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk factor (only 1/4 of patients in Poland and in CEE countries are on the low-density lipoprotein cholesterol (LDL-C) goal). To improve this, clear and simple diagnostic criteria should be introduced for all components of the lipid profile. These are the updated guidelines of the two main scientific societies in Poland in the area – the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA), which, in comparison to those from 2020, introduce few important changes in recommendations (two main lipid targets, new recommendations on LDL-C measurements, calculations new goals for triglycerides, new recommendations on remnants and small dense LDL) that should help the practitioners to be early with the diagnosis of lipid disorders and in the effective monitoring (after therapy initiation), and in the consequence to avoid the first and recurrent cardiovascular events.

Publisher

Index Copernicus

Reference81 articles.

1. Banach M, Jankowski P, Jóżwiak J, et al. PoLA/CFPiP/PCSGuidelines for the Management of Dyslipidaemias for familyPhysicians 2016. Arch Med Sci. 2017; 13: 1–45.

2. Langlois MR, Nordestgaard BG, Langsted A, et al. for the EuropeanAtherosclerosis Society (EAS) and the European federationof Clinical Chemistry and Laboratory Medicine (EFLM)Joint Consensus Initiative. Quantifying atherogenic lipoproteinsfor lipid-lowering strategies: consensus-based recommendationsfrom EAS and EFLM. Clin Chem Lab Med. 2020;58(4): 496–517; https://doi.org/10.1515/cclm-2019-1253.

3. Langlois MR, Chapman MJ, Cobbaert C, et al. for the EuropeanAtherosclerosis Society (EAS) and the European federation ofClinical Chemistry and Laboratory Medicine (EFLM) Joint ConsensusInitiative. Quantifying Atherogenic Lipoproteins: Currentand future Challenges in the Era of Personalized Medicine andVery Low Concentrations of LDL Cholesterol. A Consensus Statementfrom EAS and EFLM. Clin Chem. 2018; 64: 1006–1033.

4. The Task force for the Management of Dyslipidaemias of theEuropean Society of Cardiology (ESC) and European AtherosclerosisSociety (EAS). 2016 ESC/EAS Guidelines for the managementof dyslipidaemias: lipid modification to reduce cardiovascularrisk. Eur Heart J. 2019; 40. doi: 10.1093/eurheartj/ehz455.

5. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disordersin Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.